Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.78 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.78 |
| ▸ | USP2 | O75604 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troleandomycin SCHEMBL125071 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCB1USP2LMNAPGR | |
| Troleandomycin SCHEMBL29470683 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCB1USP2LMNAPGR | |
| Troleandomycin SCHEMBL125070 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCB1USP2LMNAPGR | |
| Troleandomycin SCHEMBL664623 | 0.88 | CYP3A4 (1.00) | CYP3A4ABCB1USP2LMNAPGR | |
| Oleandomycin SCHEMBL10028439 | 0.87 | CYP3A4 (1.00) | CYP3A4ABCB1USP2LMNAMLNR | |
| Oleandomycin SCHEMBL3716 | 0.87 | CYP3A4 (1.00) | CYP3A4ABCB1USP2LMNAMLNR | |
| Oleandomycin SCHEMBL29684259 | 0.87 | CYP3A4 (1.00) | CYP3A4ABCB1USP2LMNAMLNR | |
| Oleandomycin SCHEMBL3717 | 0.87 | CYP3A4 (1.00) | CYP3A4ABCB1USP2LMNAMLNR | |
| Oleandomycin SCHEMBL950913 | 0.86 | CYP3A4 (0.96) | CYP3A4ABCB1USP2LMNAMLNR | |
| Oleandomycin SCHEMBL9807053 | 0.86 | CYP3A4 (0.99) | CYP3A4ABCB1USP2LMNAMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3932409-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS CAUSED BY CORONAVIRUSES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2022-01-05 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| WO-2022002789-A1 | COMPOUNDS SELECTED FROM CLARITHROMYCIN AND LEXITHROMYCIN FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS CAUSED BY CORONAVIRUSES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-01-06 | — | — | WO | disclosed |
| EP-3932409-A1 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS CAUSED BY CORONAVIRUSES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2022-01-05 | — | — | EP | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP3A4 4858/4885ABCB1 1042/4885USP2 653/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP3A4 4863/4885ABCB1 1312/4885USP2 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.